Alliancebernstein L.P. Has $145.66 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Alliancebernstein L.P. increased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 8.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,779,362 shares of the company's stock after purchasing an additional 133,448 shares during the period. Alliancebernstein L.P. owned approximately 1.43% of Vaxcyte worth $145,659,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Whipplewood Advisors LLC bought a new stake in shares of Vaxcyte during the 4th quarter worth $28,000. Smartleaf Asset Management LLC boosted its position in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after acquiring an additional 260 shares during the period. Blue Trust Inc. grew its stake in shares of Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after acquiring an additional 371 shares during the last quarter. Assetmark Inc. increased its position in Vaxcyte by 77,500.0% during the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock worth $64,000 after acquiring an additional 775 shares during the period. Finally, Nomura Asset Management Co. Ltd. bought a new stake in Vaxcyte in the 3rd quarter valued at $92,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Teri Loxam sold 6,250 shares of the firm's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now owns 7,175 shares of the company's stock, valued at approximately $610,664.25. This trade represents a 46.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the sale, the chief financial officer now owns 109,491 shares of the company's stock, valued at approximately $9,472,066.41. This represents a 6.81 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,250 shares of company stock worth $3,170,738 in the last quarter. Insiders own 3.10% of the company's stock.

Remove Ads

Vaxcyte Price Performance

Shares of PCVX traded up $1.04 on Friday, hitting $31.60. The company's stock had a trading volume of 5,690,652 shares, compared to its average volume of 1,119,961. The company has a 50 day moving average price of $74.59 and a 200 day moving average price of $89.66. The company has a market capitalization of $4.07 billion, a PE ratio of -6.87 and a beta of 1.26. Vaxcyte, Inc. has a fifty-two week low of $29.57 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.14. On average, equities analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on PCVX shares. Bank of America reduced their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. The Goldman Sachs Group decreased their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Needham & Company LLC dropped their price objective on shares of Vaxcyte from $140.00 to $90.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Finally, Guggenheim reissued a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $136.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.